###begin article-title 0
Overexpressed TP73 induces apoptosis in medulloblastoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 71 79 <span type="species:ncbi:9606">Children</span>
###xml 546 553 <span type="species:ncbi:9606">patient</span>
Medulloblastoma is the most common malignant brain tumor of childhood. Children who relapse usually die of their disease, which reflects resistance to radiation and/or chemotherapy. Improvements in outcome require a better understanding of the molecular basis of medulloblastoma growth and treatment response. TP73 is a member of the TP53 tumor suppressor gene family that has been found to be overexpressed in a variety of tumors and mediates apoptotic responses to genotoxic stress. In this study, we assessed expression of TP73 RNA species in patient tumor specimens and in medulloblastoma cell lines, and manipulated expression of full-length TAp73 and amino-terminal truncated DeltaNp73 to assess their effects on growth.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 277 282 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 448 453 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
We analyzed medulloblastoma samples from thirty-four pediatric patients and the established medulloblastoma cell lines, Daoy and D283MED, for expression of TP73 RNA including the full-length transcript and the 5'-terminal variants that encode the DeltaNp73 isoform, as well as TP53 RNA using quantitative real time-RTPCR. Protein expression of TAp73 and DeltaNp73 was quantitated with immunoblotting methods. Clinical outcome was analyzed based on TP73 RNA and p53 protein expression. To determine effects of overexpression or knock-down of TAp73 and DeltaNp73 on cell cycle and apoptosis, we analyzed transiently transfected medulloblastoma cell lines with flow cytometric and TUNEL methods.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 527 536 519 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
Patient medulloblastoma samples and cell lines expressed full-length and 5'-terminal variant TP73 RNA species in 100-fold excess compared to non-neoplastic brain controls. Western immunoblot analysis confirmed their elevated levels of TAp73 and amino-terminal truncated DeltaNp73 proteins. Kaplan-Meier analysis revealed trends toward favorable overall and progression-free survival of patients whose tumors display TAp73 RNA overexpression. Overexpression of TAp73 or DeltaNp73 induced apoptosis under basal growth conditions in vitro and sensitized them to cell death in response to chemotherapeutic agents.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
These results indicate that primary medulloblastomas express significant levels of TP73 isoforms, and suggest that they can modulate the survival and genotoxic responsiveness of medulloblastomas cells.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">children</span>
Medulloblastoma is the most common malignant brain tumor of childhood [1,2]. Treatment with surgery, radiation, and chemotherapy successfully cures many patients, but survivors can suffer significant long-term toxicities affecting their neurocognitive and growth potential [3]. Despite clinical advances, up to 30% of children with medulloblastoma experience tumor progression or recurrence, for which no curative therapy exists. The lack of more effective, less toxic therapies stems from our imperfect understanding of the molecular processes that underlie medulloblastoma growth.
###end p 11
###begin p 12
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 307 311 307 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 641 646 641 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Trp53</italic>
###xml 655 663 655 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Patched </italic>
###xml 682 689 682 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch+/-</italic>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 852 857 852 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 976 981 976 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1119 1134 1119 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type TP53 </italic>
###xml 1135 1136 1135 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
###xml 625 631 <span type="species:ncbi:10090">murine</span>
###xml 691 696 <span type="species:ncbi:10090">mouse</span>
Although the TP53 tumor suppressor gene (17p13.1) is mutated in approximately half of human malignancies, it is rarely mutated in medulloblastoma [4-7]. However, several lines of evidence suggest that the TP53 pathway is perturbed in medulloblastoma. Frank et al. have described abnormalities of the p53-p14ARF pathway in the large cell/anaplastic variant of medulloblastoma [8,9]. Our collaborators have noted significant nuclear p53 immunopositivity consistent with its accumulation and potential mutation in approximately 50% of primary human medulloblastoma examined [A. Adesina, personal communication]. Deletion of the murine homolog, Trp53, in the Patched haploinsufficient (Ptch+/-) mouse model increases the incidence of spontaneous medulloblastoma from approximately 15% to 100% [10]. Individuals with Li-Fraumeni syndrome who carry germline TP53 mutations are at increased risk for developing medulloblastoma, but fewer than 10% of sporadic medulloblastoma display TP53 mutations [11,12]. There is also evidence that the activity of p53 is regulated by alternate mechanisms as observed in other cancers with wild-type TP53 [4].
###end p 12
###begin p 13
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 364 373 364 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 758 760 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 763 765 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 766 768 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 988 990 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 991 993 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 906 913 <span type="species:ncbi:9606">patient</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
While mutation of TP53 itself might not be frequently involved, genes related to TP53 may play a role in medulloblastoma [8]. TP73 is a member of the TP53 gene family. Full-length TP73-encoded protein, TAp73, is similar in structure and shares functions with p53 as a candidate tumor suppressor. It is able to activate p53-responsive genes and to induce apoptosis in vitro [13]. Differential transcription and alternative splicing of TP73 gives rise to at least 35 distinct RNA species and 14 described protein isoforms. Several 5'-variant RNA species (DeltaNp73, DeltaN'p73, DeltaEx2p73, and DeltaEx2/3p73) are translated into the amino-terminal truncated isoform, DeltaNp73, which displays anti-apoptotic effects in tumor cells and primary neurons (Figure 1A) [14,15]. Importantly, several recent studies have demonstrated correlation between the relative expression of TA and/or DeltaNp73 isoforms with patient survival for a variety of epithelial cancers occurring in adult patients [16-19].
###end p 13
###begin p 14
###xml 121 125 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 0 125 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Primary medulloblastoma specimens and medulloblastoma cell lines overexpress TAp73 and &#916;Np73 RNA species relative to <italic>TP53</italic></bold>
###xml 127 131 123 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 131 136 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 208 212 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 310 314 306 310 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 658 662 646 650 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 778 783 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 845 851 833 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 878 883 866 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 998 1003 982 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 1073 1080 1041 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Columns</italic>
###xml 1073 1080 1041 1048 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Columns</italic></bold>
###xml 1125 1135 1093 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 1125 1135 1093 1103 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>error bars</italic></bold>
###xml 1148 1154 1114 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y-axis</italic>
###xml 1148 1154 1114 1120 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Y-axis</italic></bold>
###xml 1219 1225 1185 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 383 388 <span type="species:ncbi:9606">human</span>
###xml 512 517 <span type="species:ncbi:9606">human</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
###xml 699 707 <span type="species:ncbi:9606">patients</span>
###xml 809 814 <span type="species:ncbi:9606">human</span>
###xml 1183 1188 <span type="species:ncbi:9606">human</span>
Primary medulloblastoma specimens and medulloblastoma cell lines overexpress TAp73 and DeltaNp73 RNA species relative to TP53. (A) TP73 gene and relative location of isoform-specific primers for qRT-RTPCR of TP73. Exons are depicted as boxes with overlying arrows corresponding to location of primers for PCR. (B) Established medulloblastoma cell lines, Daoy and D283MED (D283), and human adult cerebellum (Cbl) express high levels of TAp73 and amino-terminal splice variants encoding DeltaNp73 in comparison to human fetal brain. Primary medulloblastoma (MB) samples from patients (n = 34) display similar overexpression of TAp73 and DeltaNp73 RNA species. (C) Primary medulloblastoma samples from patients (n = 34) display overexpression of TAp73 and amino-terminal truncated TP73 RNA variants, relative to human fetal brain and normalized to GAPDH expression. By comparison, TP53 RNA is relatively underexpressed. Total DeltaNp73 represents the sum of expression of all amino-terminal-truncated TP73 RNA variants (DeltaNp73, DeltaN'p73, DeltaEx2p73, and DeltaEx2/3p73). Columns, mean expression of at least 2 experiments; error bars, +/- S.E.M. Y-axis, RNA expression relative to human fetal brain and normalized to GAPDH expression (N.B. log-scale).
###end p 14
###begin p 15
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Surveys have demonstrated overexpression of TP73 RNA in malignancies including colon and hepatocellular carcinoma, and neuroblastoma [20-22]. Neurodevelopmental pathways of clinical significance in neuroblastoma have also been implicated in medulloblastoma. A limited scale study failed to detect loss of heterozygosity or mutation of TP73 in five medulloblastoma samples [23]. However, to date no studies have examined the relative expression of TAp73 and DeltaNp73 in medulloblastoma.
###end p 15
###begin p 16
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 448 462 438 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type TP53</italic>
###xml 624 629 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Here we report TP73 overexpression in a series of primary human medulloblastoma and in established medulloblastoma cell lines, relative to normal brain tissue. Kaplan-Meier analysis revealed trends toward favorable overall and progression-free survival of patients whose tumors display TAp73 RNA overexpression. Functional data indicate that overexpression of TAp73beta and DeltaNp73beta induces apoptosis in transfected medulloblastoma cells with wild-type TP53. These results support the hypothesis that medulloblastoma express significant levels of p73 isoforms that can modulate survival. Our results support a role for TP73 in the growth of medulloblastoma and its response to genotoxic therapies.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Primary medulloblastoma specimens and medulloblastoma cell lines
###end title 18
###begin p 19
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 55 63 <span type="species:ncbi:9606">children</span>
###xml 105 113 <span type="species:ncbi:9606">Children</span>
Thirty-four medulloblastoma samples were obtained from children diagnosed between 1996 and 2004 at Texas Children's Hospital (Houston, TX) upon informed consent for an institutional review board-approved protocol (Table 1). All specimens were obtained at the time of diagnosis, snap-frozen and stored in liquid nitrogen. Histologic diagnoses were confirmed by pathologic review according to WHO criteria [12].
###end p 19
###begin p 20
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient and tumor characteristics
###end p 20
###begin p 21
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 301 309 <span type="species:ncbi:9606">Patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
Gross total resection was achieved in twenty-four patients. Chemotherapy for most patients consisted of cisplatin and vincristine, with combinations of carboplatin, etoposide, cyclophosphamide or lomustine. Sixteen patients received intensified chemotherapy with autologous stem cell support [24-27]. Patients greater than 36 months old received craniospinal irradiation 2400 +/- 360 centiGray (cGy) with a tumor dose of 5300 +/- 720 cGy. Median age at diagnosis was 78.9 months (range 12-216; mean 84 +/- 4.3 months (+/- S.E.M.)) with median follow up of 42 months (range 4-88; mean 45 +/- 3.9 months). For survival analysis, patients were stratified into two groups based on the median expression of TAp73 RNA in primary medulloblastoma tumor samples.
###end p 21
###begin p 22
###xml 350 351 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 353 358 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 384 394 378 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
###xml 409 411 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 412 414 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 290 294 <span type="species:ncbi:9913">calf</span>
Established human medulloblastoma cell lines, Daoy and D283MED (D283), (American Type Culture Collection, Manassas, VA) were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) with high glucose (6 g/liter), 2 mM l-glutamine and 10% (vol/vol) heat-inactivated fetal calf serum (Invitrogen, Carlsbad, CA) at 37degreesC in 5% CO2. TP53 is mutated in Daoy and is wild-type in D283 cells [28,29]. For treatment studies, cells were exposed to etoposide (VP-16, 1-10 muM), cisplatin (CDDP, 5-25 muM), or vehicle (DMSO, 0.02%) control in complete media.
###end p 22
###begin title 23
Quantitative real-time RTPCR (qRT-RTPCR) analysis
###end title 23
###begin p 24
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 274 279 <span type="species:ncbi:9606">human</span>
Total cellular RNA was extracted with either TRIzol (Invitrogen, Carlsbad, CA) or RNeasy (Qiagen, Valencia, CA) based on tissue abundance, according to the manufacturers' recommendations. For reference controls, we used commercially available RNA from human fetal brain and human adult cerebellum (Stratagene, La Jolla, CA). RNA integrity was verified on an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA).
###end p 24
###begin p 25
###xml 269 271 269 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">12</sub>
###xml 391 395 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 665 667 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 176 205 <span type="species:ncbi:11801">Moloney murine leukemia virus</span>
###xml 557 562 <span type="species:ncbi:9606">human</span>
RNA was analyzed by qRT-RTPCR performed with the Bio-Rad iQ4 Multicolor Real-Time iCycler (Bio-Rad Laboratories, Hercules, CA). Total cellular RNA was reverse transcribed with Moloney murine leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA) and oligo-(dT)12, using standard methods. PCR reactions containing cDNA, iQ Syber Green Supermix (Bio-Rad Laboratories) and primers for TP53, full-length or 5'-terminal variant isoforms of TP73 were performed for 40 cycles in triplicate (Figure 1A). Specific primers detect RNA species for full-length human TP73 (TAp73) and 5'-terminal variants (DeltaNp73, DeltaN'p73, DeltaEx2p73, and DeltaEx2/3p73) (Figure 1A):
###end p 25
###begin p 26
TAp73 sense, 5'-CCGGCGTGGGGAAGATGG-3' and
###end p 26
###begin p 27
antisense, 5'-TTGAACTGGGCCATGACAGATG-3';
###end p 27
###begin p 28
DeltaNp73 (and DeltaN'p73) sense, 5'-ACGGCCCAGTTCAATCTGC-3' and
###end p 28
###begin p 29
antisense, 5'-CTGGGGTGTAGGGGCTGG-3';
###end p 29
###begin p 30
DeltaN'p73 sense, 5'-TCGACCTTCCCCAGTCAAGC-3' and
###end p 30
###begin p 31
antisense, 5'-TGGGACGAGGCATGGATCTG-3';
###end p 31
###begin p 32
DeltaEx2p73 sense, 5'-AGGGAACCAGACAGCACCTA-3' and
###end p 32
###begin p 33
antisense, 5'-ACGTCCATGCTGGAATCCG-3';
###end p 33
###begin p 34
DeltaEx2/3p73 sense, 5'-CAGGCCCAGTTCAATCTGCTG-3' and
###end p 34
###begin p 35
antisense, 5'-GAGTGGGTGGGCACGCTG-3';
###end p 35
###begin p 36
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
TP53 sense, 5'-CCATCTACAAGCAGTCACAGC-3' and
###end p 36
###begin p 37
antisense, 5'-GAGTCTTCCAGTGTGAGATG-3';
###end p 37
###begin p 38
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
GAPDH sense, 5'-AAGGTGAAGGTCGGAGTCAA-3' and
###end p 38
###begin p 39
antisense, 5'-AATGAAGGGGTCATTGATGG-3'.
###end p 39
###begin p 40
Because DeltaNp73 lacks unique primer sequences, its relative abundance was calculated by subtracting from the relative copy number of DeltaN'p73 (using the DeltaN'p73-specific upstream primer pair) from those of DeltaNp73 and DeltaN'p73 determined using the common primer pair.
###end p 40
###begin p 41
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 184 189 <span type="species:ncbi:9606">human</span>
Amplification products were verified by agarose gel electrophoresis, melting curves, and sequencing. Gene expression was normalized internally to GAPDH expression, relative to control human fetal brain RNA as a tissue reference, and accounting for differences in primer efficiencies [30]. Results from at least two separate experiments were analyzed.
###end p 41
###begin title 42
Western immunoblot analysis
###end title 42
###begin p 43
###xml 166 167 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 789 794 782 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
Cell lysates were prepared using standard methods. Briefly, protein was extracted from frozen tissue with boiling lysis buffer (0.5% SDS, 50 mM Tris-Cl, pH 8, 5 mM Na2EDTA) containing 2% beta-mercaptoethanol for 5 minutes and tissue was homogenized using a PT1200CL Polytron (Kinematica, Switzerland), followed by shearing through a 22-guage needle and clarification by brief centrifugation. Yields were quantitated using the RC-DC Protein assay (Bio-Rad Laboratories, Hercules, CA). Lysates were separated by SDS-PAGE and transferred onto PVDF membranes for immunoblotting with antibodies against p73 (H-79, Santa Cruz Biotechnology, Santa Cruz, CA; and GC-15, Pharmingen, San Jose, CA), DeltaNp73 (IMG-313, Imgenex, San Diego, CA), and p53 (FL-393 or DO-1, Santa Cruz Biotechnology), p21Waf1 (Ab-11(CP74), Thermo Fisher Scientific, Fremont, CA), PARP (Cell Signaling Technology, Danvers, MA), and beta-actin (C-2, Santa Cruz Biotechnology).
###end p 43
###begin p 44
###xml 489 493 <span type="species:ncbi:9925">goat</span>
###xml 499 504 <span type="species:ncbi:10090">mouse</span>
Chemiluminescent detection of primary antibody staining was performed using HRP-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) with LumiGLO substrate, according to manufacturer's recommendations (Cell Signaling Technologies, Beverly, MA). Western blots were exposed to Kodak BioMax MS film (Kodak, New Haven, CT), developed, and analyzed with Image Station 2000R (Kodak). Alternatively, staining with fluorescent secondary antibody (Alexa Fluor 680 nm-conjugated goat anti-mouse IgG, Invitrogen) was visualized using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, Nebraska). Intensity of immunostaining was quantitated using ImageQuant 5.2 (Molecular Dynamics, Piscataway, NJ). The intensity of each protein band was normalized to beta-actin immunostaining as an internal loading control, and compared to results in the D283 cell line as a tissue reference. Results from at least two separate experiments were analyzed.
###end p 44
###begin title 45
###xml 40 45 <span type="species:ncbi:9606">human</span>
Immunohistochemical analysis of primary human tumors
###end title 45
###begin p 46
###xml 237 238 237 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 379 380 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 381 382 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 428 432 <span type="species:ncbi:9925">goat</span>
###xml 689 693 <span type="species:ncbi:9925">goat</span>
###xml 699 704 <span type="species:ncbi:10090">mouse</span>
For immunostaining, five micron thick sections were prepared from formalin-fixed paraffin embedded medulloblastoma specimens. Tissue sections were deparaffinized in xylene, followed by graded hydration in 100% ethanol, 70% ethanol, and H2O. Antigen retrieval was performed by boiling in DAKO citrate for 25 min (Dako, Carpinteria, CA). Endogenous peroxidase was blocked with 3% H202/Methanol for 15 min, then incubated with 20% goat serum for 20 min. Sections were incubated with anti-p53 antibody (D07, Novocastra, Newcastle Upon Tyne, UK) for 1 hour at 25degreesC. This antibody is reactive for both wild-type and mutant p53 proteins. This was followed by incubation with HRP-conjugated goat anti-mouse secondary antibody for 30 min. Washed sections were developed using 3-amino-9-ethyl carbazole as the chromogen. The immunostained sections were graded semi-quantitatively for degrees of staining intensity (negative, 0; positive, 1+ to 3+) by neuropathologists blinded to clinical information.
###end p 46
###begin title 47
Gene expression and post-transcriptional gene silencing transfections
###end title 47
###begin p 48
###xml 531 533 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 534 536 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 201 222 <span type="species:ncbi:10359">human cytomegalovirus</span>
###xml 224 227 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 390 393 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 434 439 <span type="species:ncbi:9606">human</span>
###xml 466 471 <span type="species:ncbi:10090">mouse</span>
Daoy and D283 cell lines were transiently transfected with expression and reporter plasmids using Lipofectin according to manufacturer's recommendations (Invitrogen). Expression plasmids included: the human cytomegalovirus (CMV) immediate-early (IE) promoter-driven pP53-EGFP plasmid, encoding a p53-enhanced green fluorescent protein (GFP) fusion protein (Clontech, Mountainview, CA), and CMV IE promoter-driven hemaglutinnin-tagged human TAp73beta- and Myc-tagged mouse DeltaNp73beta-encoding plasmids were previously described [14,31]. In each transfection, the expression plasmids were supplemented by empty vector (pcDNA3.1, Invitrogen) to achieve an equivalent total plasmid DNA concentration. For flow cytometry, the EGFP-expressing pmaxGFP plasmid (Amaxa, Gaithersburg, MD) provided transfection controls.
###end p 48
###begin p 49
###xml 154 159 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 197 199 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 237 242 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
Transient small interfering RNA (siRNA)-mediated silencing of TAp73 and DeltaNp73 was achieved using the following siRNAs: TAp73 (targeting a sequence in TP73 exon 3), 5'-AACGGAUUCCAGCAUGGACGU-3' [32]; DeltaNp73 (targeting a sequence in TP73 exon 3B to exon 4), 5'-AACCUCGCCACGGCCCAGUUC-3'. Transfections with equimolar concentrations of validated siCONTROL non-targeting siRNA Pool#1 (Dharmacon, Lafayette, CO) provided negative controls. Daoy and D283 cells were grown to 50% confluency in a 6-well plate and transfected for 6 hours in Opti-MEM serum-free media (Invitrogen) with Oligofectamine Reagent, according to manufacturer recommendations (Invitrogen). Cells were allowed to recover from transfection for 24-48 hours and were then treated for 24 hours before harvesting for RNA or protein isolation. The resulting expression of target and off-target (e.g. beta-actin and GAPDH) proteins were assayed by Western immunoblot analysis, relative to cells transfected with the negative control siRNA (Dharmacon).
###end p 49
###begin title 50
Apoptosis detection by flow cytometry and terminal deoxynucleotidyl transferase-mediated biotinylated-dUTP nick end-labeling (TUNEL)
###end title 50
###begin p 51
###xml 662 663 661 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 665 667 664 666 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 953 954 952 953 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 956 958 955 957 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
We monitored DNA-indices for cell cycle analysis by multiparametric flow cytometry using standard methods. Analyses were performed using a Becton Dickinson FACScan flow cytometer (BD Biosciences, San Jose, CA) for the detection of cells stained with propidium iodide (PI) and a 488 nm laser with filter combination for fluorescein isothiocyanate (FITC) and GFP. Single cell suspensions were isolated from culture, fixed in methanol, and stained with PI (100 mug/mL in PBS). Each histogram represents 10,000-100,000 cells for measuring DNA-index and cell cycle. Histogram analysis was performed with the CellQuest program (BD Biosciences). We calculated the sub-G0/G1 peak in the hypodiploid distribution below a DNA index of one (< 2n). Because the nucleus becomes fragmented during apoptosis and numerous individual chromatin fragments may be present in a single cell, the percentage of objects with a fractional DNA-content is represented by the sub-G0/G1 peak. Apoptotic nuclei were identified as a hypodiploid DNA peak, and were distinguished from cell debris on the basis of forward light scatter and PI fluorescence.
###end p 51
###begin p 52
###xml 35 36 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
To detect apoptotic nuclei in sub-G0/G1 peaks, a subset of unstained cells was analyzed for DNA-fragmentation using Frag-EL DNA fragmentation detection kit, according to manufacturer's recommendations (Oncogene Research Products, Cambridge, MA). Cells were also counter stained with PI for DNA quantification. FITC signal was detected on one channel in the logarithmic mode, while UV fluorescence (PI) was recorded in the linear mode on a separate channel. For each measurement, at least 10,000 cells were analyzed. We used CellQuest software for multiparametric calculations and analyses. Cut-off negative and positive cells resulted from FITC-fluorescence isotype control measurements for each sample.
###end p 52
###begin title 53
Statistical considerations
###end title 53
###begin p 54
###xml 245 251 245 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TAp73 </italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 791 796 791 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 201 209 <span type="species:ncbi:9606">Patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 765 772 <span type="species:ncbi:9606">patient</span>
Clinical outcomes were analyzed for progression-free and overall survival using the method of Kaplan and Meier (StatView, v. 4.5, Abacus Concepts, Berkeley, CA; GraphPad Software, v.4; San Diego, CA). Patients were stratified according to tumor TAp73 RNA levels, normalized to GAPDH and relative to expression in fetal brain control RNA. The "high" expression group contained patients with tumor expression of TAp73 RNA greater than or equal to the median value of all tumors analyzed. The "low" expression group contained patients with tumor expression of TAp73 RNA less than the median value of all tumors analyzed. The significance of survival differences was calculated by logrank testing, which was applied to assess the significance of specific factors (e.g. patient stratification by TP73 expression level). To determine if expression levels correlated with other clinical and tumor characteristics, we applied Fisher's Exact testing.
###end p 54
###begin title 55
Results
###end title 55
###begin title 56
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
Medulloblastoma cell lines and primary medulloblastoma specimens overexpress TP73 RNA species relative to normal brain tissue
###end title 56
###begin p 57
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 382 388 358 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 396 398 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 401 405 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 286 291 <span type="species:ncbi:9606">human</span>
In order to examine the involvement of TP73 in medulloblastoma growth, we surveyed expression levels of TAp73 and total DeltaNp73 variants (DeltaNp73, DeltaN'p73, DeltaEx2p73, and DeltaEx2/3p73) using qRT-RTPCR. Compared to human fetal brain, Daoy and D283 cell lines, as well as adult human cerebellum overexpressed TAp73 and total DeltaNp73 RNA variants, internally normalized to GAPDH (Figure 1B). TP53-mutant Daoy cells displayed much higher levels of TAp73 and of total DeltaNp73 RNA (9-fold +/- 1 (mean +/- S.E.M.) and 12-fold +/- 2, respectively) than fetal brain. D283 cells expressed even higher levels of TAp73 and total DeltaNp73 (116-fold +/- 35 and 74-fold +/- 16, respectively).
###end p 57
###begin p 58
###xml 29 38 29 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 81 88 81 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 309 313 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B&#8211;C</xref>
###xml 335 336 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 445 450 <span type="species:ncbi:9606">human</span>
Since established cell lines in vitro differ significantly from medulloblastomas in vivo, we analyzed primary tumor specimens from 34 patients. By qRT-RTPCR, the RNA expression of TAp73 and total DeltaNp73 variants was similar among primary medulloblastoma samples but markedly higher than cell lines (Figure 1B-C, see Additional file 1). Primary tumors displayed 282-fold (+/- 65) more TAp73 and 194-fold (+/- 36) more total DeltaNp73 RNA than human fetal brain.
###end p 58
###begin p 59
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 273 275 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 352 357 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 398 400 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 502 507 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 547 549 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 679 684 667 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 82 87 <span type="species:ncbi:9606">human</span>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 634 639 <span type="species:ncbi:9606">human</span>
###xml 702 707 <span type="species:ncbi:9606">human</span>
To provide an additional tissue control, we analyzed TP73 5'-variants in RNA from human adult cerebellum. Compared to human fetal brain, adult cerebellum also displayed overexpression of TAp73 and total DeltaNp73 RNA (24-fold +/- 6 and 48-fold +/- 5, respectively) (Figure 1B). Importantly, primary medulloblastoma samples expressed about 10-fold more TP73 RNA than normal adult cerebellum (Figure 1B). Of the four control tissue controls, male and female fetal brain RNA (Stratagene) revealed similar TP73 expression profiles. As shown in Figure 1B, adult cerebellum expressed 10 to 100-fold more TAp73 and DeltaNp73 RNA compared to human fetal brain controls. We also examined TP73 RNA expression in human adult frontal cortex (Stratagene) by qRT-RTPCR, but found minimal expression of TAp73 or DeltaNp73 transcripts (data not shown).
###end p 59
###begin p 60
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 445 450 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 626 631 618 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 760 762 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 765 770 753 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 896 901 880 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 320 325 <span type="species:ncbi:9606">human</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
###xml 480 485 <span type="species:ncbi:9606">human</span>
###xml 558 563 <span type="species:ncbi:9606">human</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
###xml 729 734 <span type="species:ncbi:9606">human</span>
Since the effects of p73 isoforms likely reflect their ability to interact with p53, we assessed TP53 expression using primers in exons 5 and 7 to detect all known TP53 splice variants (Figure 1B, see Additional file 1). The Daoy cell line, which harbors a p53 mutation (C242F), expressed TP53 RNA at a level similar to human fetal brain, 1.1-fold (+/- 0.42), but 15-fold (+/- 2.0) more than human adult cerebellum. The D283 cell line expressed TP53 RNA at much lower levels than human fetal brain, 0.05-fold (+/- 0.016) and 0.43-fold (+/- 0.14) relative to human adult cerebellum. Primary medulloblastoma specimens displayed TP53 levels 1.4-fold (+/- 0.12) higher than in human fetal brain, and 12-fold (+/- 1.0) higher than in human adult cerebellum (Figure 1B). TP53 copy numbers in cell lines were at least one log lower than either TAp73 or total DeltaNp73 levels, whereas in primary tumors TP53 was at least two logs lower than either TAp73 or total DeltaNp73.
###end p 60
###begin title 61
Primary tumors and cell lines overexpress TAp73 and DeltaNp73 proteins
###end title 61
###begin p 62
###xml 240 242 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 308 312 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A&#8211;B</xref>
###xml 334 335 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
In order to examine expression of p73 proteins in established cell lines and primary medulloblastoma samples, we employed monoclonal (GC-15) and polyclonal (H-79) antibodies, which recognize full-length TAp73 and amino-truncated DeltaNp73 [33], and a DeltaNp73-specific monoclonal antibody (IMG-313) (Figure 2A-B, see Additional file 2). Protein levels were internally normalized to beta-actin expression as a loading control and compared to expression in the D283 cell line as a reference.
###end p 62
###begin p 63
###xml 0 105 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Primary medulloblastoma specimens and medulloblastoma cell lines overexpress TAp73 and &#916;Np73 proteins</bold>
###xml 187 191 179 183 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 260 264 252 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 830 834 812 816 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
Primary medulloblastoma specimens and medulloblastoma cell lines overexpress TAp73 and DeltaNp73 proteins. Western immunoblot analysis of p53, TAp73, and DeltaNp73 protein expression in: (A) established medulloblastoma cell lines, Daoy and D283MED (D283), and (B) primary medulloblastoma specimens. Immunoblots for p53 (FL-393) or p73 proteins (H-79, GC-15, and IMG-313) were stripped and re-probed for beta-actin (C-2) to control for protein loading. Columns marked with numbers 1-8 represent Western blots of eight different primary medulloblastoma specimens. Additional bands presumably represent additional carboxy-terminal isoforms of TAp73 and DeltaNp73. Relative migration of molecular weight standards is shown at left. Shown are representative blots from at least 3 experiments, normalized to ss-actin (mean +/- S.E.M.). (C) Primary medulloblastoma (MB) specimens and medulloblastoma cell lines display significant expression of TAp73, DeltaNp73, and p53 proteins as quantitated on Western blots. Shown are representative blots from at least 3 experiments, normalized to ss-actin (mean +/- S.E.M.).
###end p 63
###begin p 64
###xml 269 271 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 438 440 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
The H-79 polyclonal antibody, raised against a conserved amino-terminal peptide sequence, recognizes the major carboxy-terminal variants of TAp73 (TAp73alpha, 75-80 kDa; and TAp73beta, 60-65 kDa) and of DeltaNp73 (DeltaNp73alpha, 70-75 kDa; and DeltaNp73beta, 50 kDa) [34]. Both established medulloblastoma cell lines, Daoy and D283, exhibited significant, although different levels of TAp73 and DeltaNp73, relative to beta-actin (Figure 2C). Primary tumor specimens (n = 8), in contrast, exhibited more DeltaNp73 (1.7-fold D283 levels (+/- 0.34)) compared to TAp73 (0.55-fold +/- 0.2).
###end p 64
###begin p 65
###xml 242 246 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A&#8211;B</xref>
###xml 358 362 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A&#8211;B</xref>
###xml 513 515 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
The GC-15 monoclonal antibody, raised against a conserved carboxy-terminal peptide sequence, found in p73beta isoforms, also detected comparable levels of TAp73 protein in established cell lines and in primary medulloblastoma samples (Figure 2A-B). To confirm the identity of putative DeltaNp73 bands, we used the DeltaNp73-specific IMG-313 antibody (Figure 2A-B). Based on their predicted molecular weights, the other detected isoforms presumably represent other carboxy-terminal variants as reported by others [35]. The equivalent expression of TAp73 and DeltaNp73 protein in D283 cells resembled its RNA expression pattern by qRT-RTPCR. In contrast, Daoy cells expressed slightly more TAp73 than DeltaNp73 protein, and primary tumor samples displayed higher levels of DeltaNp73 compared to TAp73 protein.
###end p 65
###begin p 66
###xml 95 99 95 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A&#8211;B</xref>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 326 336 326 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 532 537 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Primary medulloblastoma specimens and cell lines displayed variable p53 protein levels (Figure 2A-B, see Additional file 3). Daoy cells express high levels of mutant p53. The higher p53 level in Daoy cells suggests decreased turnover by MDM2-mediated degradation as commonly seen with many mutant p53 proteins. D283, which is wild-type for TP53, expresses much lower levels of p53 protein at baseline (Figure 2C). The relative p53 protein levels in established cell lines and primary medulloblastoma are similar to their pattern of TP53 RNA expression. Using antibodies with differing affinities precluded a direct comparison of p53 and p73 protein levels.
###end p 66
###begin p 67
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
Although TP53 RNA expression did not correlate with clinical outcome, immunohistochemical staining intensity of p53 protein (scored > 2+) in paraffin-embedded formalin-fixed specimens was significantly associated with worse progression-free survival (PFS) (p < 0.035, Figure 3). These findings underscore the central importance of p53, which can interact with various p73 isoforms.
###end p 67
###begin p 68
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Intensity of p53 immunostaining correlates with overall survival</bold>
###xml 114 118 114 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 122 126 122 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 134 138 134 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 174 178 174 178 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D) </bold>
###xml 326 327 326 327 <bold xmlns:xlink="http://www.w3.org/1999/xlink">.</bold>
Intensity of p53 immunostaining correlates with overall survival. Examples of medulloblastoma sections displaying (A) 1+, (B) 2+, and (C) 3+ intensity of p53 immunostaining. (D) Kaplan-Meier survival analysis illustrating association of 2+ and 3+ intensity with adverse progression-free survival (p < 0.035 by logrank testing).
###end p 68
###begin title 69
Overall and progression-free survival are associated with TAp73 overexpression
###end title 69
###begin p 70
###xml 659 663 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A&#8211;B</xref>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">children</span>
###xml 716 723 <span type="species:ncbi:9606">patient</span>
For the entire group of patients studied, the median PFS was 35.4 months (range 4.0 - 88.3; 38.1 +/- 4.5 months (mean +/- S.E.M.)). We analyzed outcome among subsets of patients with respect to clinical variables such as age, extent of primary resection, or metastatic disease at diagnosis. As established in other series, those children less than 36 months old (p < 0.160 and p < 0.126 for overall survival (OS) and progression-free survival (PFS) by logrank, respectively) or with metastatic disease (M-positive Chang stage; p < 0.044 (OS) and p < 0.024 (PFS)) displayed a trend toward worse OS and PFS, but did not achieve statistical significance (Figure 4A-B). OS and PFS were not significantly associated with patient sex, degree of initial resection, or chemotherapy regimen.
###end p 70
###begin p 71
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Medulloblastoma survival is associated with TAp73 overexpression</bold>
###xml 142 145 142 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 198 201 198 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 268 271 268 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C)</bold>
###xml 314 317 314 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D)</bold>
###xml 428 433 428 433 <bold xmlns:xlink="http://www.w3.org/1999/xlink">High </bold>
###xml 437 440 437 440 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Low</bold>
###xml 489 495 489 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 532 537 532 537 <bold xmlns:xlink="http://www.w3.org/1999/xlink">High </bold>
###xml 606 610 606 610 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Low </bold>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">Patients</span>
Medulloblastoma survival is associated with TAp73 overexpression. Kaplan-Meier analysis reveals trends toward adverse outcome associated with (A) age less than 36 months (p < 0.126 by logrank), and (B) metastatic (M+) disease at diagnosis (p < 0.024); while revealing (C) a trend toward better PFS (p < 0.052) and (D) better OS and in patients whose tumors display higher TAp73 RNA levels (p < 0.070). Patients were stratified (High vs. Low) according to tumor TAp73 levels, normalized to GAPDH and relative to fetal brain control. High = greater than or equal to the median tumor expression of TAp73 RNA. Low = less than the median tumor expression of TAp73 RNA.
###end p 71
###begin p 72
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C&#8211;D</xref>
###xml 410 414 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 537 542 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 546 551 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 618 625 <span type="species:ncbi:9606">patient</span>
The association of TP73 expression with clinical outcome in neuroblastoma, the most common malignant solid tumor of childhood, prompted our analysis of the relationship between TP73 RNA and survival in medulloblastoma patients. When stratified by tumor TAp73 RNA levels, higher expression was associated with better PFS (p < 0.052) and OS (p < 0.070) (Table 1; Figure 4C-D). We also examined RNA expression of TP53, TAp73, or DeltaNp73 variants, and histologic subtype, but found no statistically significant association with OS or PFS. TP53 and TP73 RNA levels did not correlate with other prognostic factors such as patient age, metastatic status, or extent of resection, with p values ranging from 0.35 to 1.00 (Fisher's Exact test).
###end p 72
###begin title 73
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
Genotoxic stress induces TP73 expression in medulloblastoma cell lines
###end title 73
###begin p 74
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 508 513 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 592 594 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 641 646 637 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 675 680 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 730 732 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
Because the analyzed tumor specimens were obtained before genotoxic treatment, gene expression levels do not reflect the activity of p53 and p73 isoforms. Therefore, we used medulloblastoma cell lines to assay responses to genotoxic stress in the form of chemotherapeutic agents used to treat medulloblastoma clinically (cisplatin (CDDP), etoposide (VP-16)) and another agent, doxorubicin, previously studied for TP73 induction (Figure 5A). When exposed to cytotoxic concentrations of these agents, TP53 and TP73 RNA levels, especially the DeltaN'p73 species, increased in D283 cells (Figure 5B). Although less p53 induction was observed in TP53 mutant Daoy cells, increased TP73 levels including DeltaN'p73 were detected (Figure 5C). These data indicate that in addition to post-translational stabilization, p73 levels are regulated at least in part through chemotherapy-induced p73 RNA transcription.
###end p 74
###begin p 75
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genotoxic agents induce <italic>TP73 </italic>expression and apoptosis in medulloblastoma cell lines</bold>
###xml 85 89 85 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 124 130 124 130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(CDDP)</bold>
###xml 151 159 147 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(VP-16) </bold>
###xml 186 192 178 184 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(DOXO)</bold>
###xml 210 214 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 331 335 315 319 <bold xmlns:xlink="http://www.w3.org/1999/xlink"> (B)</bold>
###xml 403 407 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 412 416 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 552 557 528 533 <bold xmlns:xlink="http://www.w3.org/1999/xlink"> (C) </bold>
###xml 572 575 548 551 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D)</bold>
###xml 780 784 756 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1</sup>
###xml 784 806 760 782 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(arrows, upper panels)</bold>
###xml 1043 1066 1010 1033 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(arrows lower panels). </bold>
Genotoxic agents induce TP73 expression and apoptosis in medulloblastoma cell lines. (A) Chemotherapeutic agents (cisplatin (CDDP) 1 microM, etoposide (VP-16) 10 microM, and doxorubicin (DOXO) 1 microM) induce TP73 expression in Daoy cells, especially DeltaN'p73 species, as determined by qRT-RTPCR normalized to GAPDH expression.  (B) CDDP-treated (1, 5, and 25 microM) D283 cells display induction of TP53 and TP73 RNA expression (including DeltaN'p73 species) - similar to results observed in CDDP-treated Daoy cells. Western immunoblots reveal that (C) Daoy cells and (D) D283 cells transiently transfected with p53-GFP expression plasmid increase expression of tagged p53-GFP protein (at a higher apparent molecular weight than native p53), as well as the p53/p73 target, p21Waf1(arrows, upper panels). Treatment with etoposide (VP-16, 1.5 microM) stabilizes wild-type p53 protein. Transient transfection with either TAp73 or DeltaNp73 expression plasmids also increased respective protein levels, normalized to ss-actin loading control. (arrows lower panels).
###end p 75
###begin p 76
###xml 188 190 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 447 451 435 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C&#8211;D</xref>
D283 and Daoy cells were also used for transfection studies to determine the effects of overexpressed TAp73 and DeltaNp73. Treatment with VP-16 stabilized p53 levels in D283 cells (Figure 5D). We examined the effects of increased p53, TAp73, and DeltaNp73 levels by transient transfection with expression plasmids. Transient transfected p53, TAp73, and DeltaNp73 could be readily distinguished on Western blots of D283 and Daoy cell lines (Figure 5C-D).
###end p 76
###begin title 77
Chemotherapy and overexpressed p53 induce apoptosis
###end title 77
###begin p 78
###xml 408 409 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 411 413 401 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 483 484 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
We investigated whether p53 induces apoptosis in medulloblastoma cells exposed to chemotherapeutic agents. Expression plasmid transfections also permitted flow cytometric analysis of the cell cycle distribution of fluorescently immunolabeled TAp73beta-, DeltaNp73beta-, and p53-overexpressing transfectants. VP-16-induced changes in apoptosis were determined by flow cytometric quantitation of cells in sub-G0/G1 fractions, which was confirmed by TUNEL analysis (see Additional file 4). Similar results were obtained with CDDP and UV irradiation (data not shown).
###end p 78
###begin p 79
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 76 78 76 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 247 257 247 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
###xml 317 318 317 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 320 321 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 554 558 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
TP53 mutant Daoy cells treated with VP-16 increased their apoptotic sub-G0/G1 population to 22.6% compared to 7.2% in untreated controls, illustrating VP-16 induced apoptosis in the absence of active p53 (Figure 6A). Overexpression of transfected wild-type p53 in Daoy cells caused increased apoptosis (10.1% in sub-G0/G1), compared to controls (7.2%) (Figure 6A). VP-16 treatment of p53-expressing Daoy transfectants further increased apoptosis (29.4%) (Figure 6A). These data indicate that transfected p53 expression partially restored p53 function in TP53-mutant Daoy cells.
###end p 79
###begin p 80
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAp73 induces apoptosis of medulloblastoma cell lines</bold>
###xml 135 138 135 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 234 237 234 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 500 504 496 500 <bold xmlns:xlink="http://www.w3.org/1999/xlink"> (C)</bold>
###xml 520 524 516 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink"> (D)</bold>
###xml 710 714 706 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1</sup>
###xml 737 745 733 741 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(arrows)</bold>
TAp73 induces apoptosis of medulloblastoma cell lines. Histograms summarizing flow cytometric analysis of cell cycle distributions of: (A) transfected Daoy cell line, illustrating the sub-G0/G1 peak representing apoptotic nuclei; and (B) transfected D283 cell line in sub-G0/G1, with plasmids and treatment with VP-16 (1.5 microM), as indicated. Y-axis, % of cells with apoptotic features by flow cytometry; X-axis, transfected plasmid(s) and culture conditions. Western immunoblots also reveal that  (C) Daoy cells and  (D) D283 cells transiently transfected with isoform-specific siRNA reveal knockdown of their respective protein levels. D283 knockdowns reduced protein expression of the p53/p73 target, p21Waf1, and cleavage of PARP (arrows).
###end p 80
###begin p 81
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 177 178 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 320 330 320 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
###xml 461 462 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 464 465 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 581 582 581 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 584 586 584 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
When exposed to VP-16, D283 controls (transfected with a GFP-expressing control plasmid) underwent increased apoptosis as indicated by an increased fraction of cells in sub-G0/G1, from 7.0 to 11.3%, (Figure 6B). These results indicate that VP-16 induces apoptosis, as described for other neuroepithelial cell types with wild-type p53. Overproduction of p53 in D283 cells by transfection of a GFP-tagged p53 expression plasmid increased apoptosis (12.0% in sub-G0/G1) compared to controls (7.0%) (Figure 6B). VP-16 treatment of p53-transfected D283 cells further increased the sub-G0/G1 population to 18.6% (Figure 6B).
###end p 81
###begin p 82
###xml 75 80 75 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
###xml 135 147 135 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink">upper panels</bold>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 228 233 228 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
###xml 288 300 288 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink">upper panels</bold>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
Overexpression of p53 in transfected Daoy cells increased expression of p21Waf1 protein, relative to control maxGFP-transfected cells (upper panels, Figure 5C). VP-16 treatment of p53-overexpressing D283 cells also increased p21Waf1 protein demonstrating the activity of transfected p53 (upper panels, Figure 5D).
###end p 82
###begin title 83
Overexpression of TAp73beta or DeltaNp73beta induces apoptosis
###end title 83
###begin p 84
###xml 152 167 149 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type TP53 </italic>
###xml 335 336 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 338 340 332 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 429 430 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 515 517 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 529 530 517 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 532 534 520 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 684 686 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
We examined the effects of TAp73 overexpression on survival. TAp73beta overexpression increased apoptosis to 19.4% from 7.0% in GFP-control transfected wild-type TP53 D283 cells, even in the absence of genotoxic stress. VP-16 treatment of TAp73beta transfectants resulting in further enhancement of chemosensitivity with 37.2% in sub-G0/G1 compared to 11.3% treated control and 19.4% in untreated TAp73beta transfectants (Figure 6). Transfected TAp73beta induced apoptosis as effectively as transfected p53 (Figure 6A). The sub-G0/G1 population in p53 mutant Daoy cells transfected with TAp73beta did not differ significantly from control transfectants under basal conditions (Figure 6B).
###end p 84
###begin p 85
###xml 226 228 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 343 344 325 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 346 347 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 357 359 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 561 571 533 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
We next asked whether DeltaNp73 affects survival in medulloblastoma cells. Rather than anti-apoptotic effects, DeltaNp73beta overexpression increases apoptosis to 17.0% compared to 7.0% in GFP-control transfected D283 (Figure 6A). Transfection of DeltaNp73beta in D283 also increased apoptosis in response to VP-16-treated D283 (29.8% in sub-G0/G1) (Figure 6A). Neither of these effects was observed in transfected p53 mutant Daoy cells. These data suggest that apoptosis and chemosensitization induced by TAp73beta and DeltaNp73beta, as in D283 cells, require wild-type p53.
###end p 85
###begin p 86
###xml 189 193 179 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1</sup>
###xml 263 268 250 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
###xml 354 366 341 353 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lower panels</bold>
###xml 375 379 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C&#8211;D</xref>
###xml 432 437 412 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
###xml 457 469 437 449 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lower panels</bold>
###xml 478 482 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C&#8211;D</xref>
###xml 601 606 571 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
###xml 614 616 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 691 696 661 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
As noted with p53 overexpression, transient transfection with expression plasmids encoding TAp73beta or DeltaNp73beta resulted in increased protein expression of the p53/p73 target gene p21Waf1. Overexpression of TAp73beta resulted in a comparable increase of p21Waf1 expression in Daoy cells and untreated D283 cells, relative to control transfectants (lower panels, Figure 5C-D). Overexpression of DeltaNp73beta also increased p21Waf1 protein expression (lower panels, Figure 5C-D). Treatment of p53-, TAp73beta - and DeltaNp73beta-transfected D283 cells with VP-16 revealed similar induction of p21Waf1 (Figure 5D). These results demonstrate the transcriptional activity of overexpressed TP73 isoforms in medulloblastoma cell lines.
###end p 86
###begin title 87
Knockdown of TAp73 or DeltaNp73 reduces target gene expression and apoptosis
###end title 87
###begin p 88
###xml 157 161 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C&#8211;D</xref>
###xml 262 267 258 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
###xml 275 277 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 388 390 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 525 527 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 591 596 579 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1 </sup>
###xml 640 642 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
Transient transfection of Daoy and D283 cells with isoform-specific siRNAs decreased TAp73 and DeltaNp73 protein expression by Western blot analysis (Figure 6C-D). In D283 transfectants, TAp73 siRNA decreased the protein expression of the p53/p73 target gene p21Waf1 (Figure 6D). As an indicator of decreased apoptosis, PARP cleavage was also decreased by TAp73 knockdown in D283 (Figure 6D). In contrast, D283 cells transfected with DeltaNp73 siRNA did not display p73 target gene induction or PARP cleavage in D283 (Figure 6D). Reducing DeltaNp73 expression siRNA resulted in decreased p21Waf1 protein as seen in TAp73 knockdowns (Figure 6D). These knockdown data complement the results of overexpression and apoptosis assays.
###end p 88
###begin title 89
Discussion
###end title 89
###begin p 90
###xml 148 153 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 499 504 483 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 583 585 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 668 670 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 671 673 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 948 950 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 382 387 <span type="species:ncbi:9606">human</span>
###xml 449 455 <span type="species:ncbi:10090">murine</span>
We have determined that primary medulloblastoma specimens and cell lines overexpress full-length TAp73 and the amino-terminal truncated variants of TP73 (DeltaNp73, DeltaN'p73, DeltaEx2p73, and DeltaEx2/3p73) at levels in excess of those found in fetal brain and normal adult cerebellum. We have also shown that adult cerebellum express more TAp73 and 5'-terminal variant RNAs than human fetal brain. This is consistent with results from studies in murine brain showing that the relative balance of TP73 expression appears to shift during development with increasing overall levels [14]. Normal neuronal differentiation requires a balance between TAp73 and DeltaNp73 [14,15]. While DeltaNp73 is necessary for adult neuronal survival, levels in excess of these physiologic anti-apoptotic levels may prevent normal cell death during development, following growth factor withdrawal, or in response to genotoxic stress such as chemotherapeutic agents [14].
###end p 90
###begin p 91
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 247 249 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 250 252 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 268 273 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 381 386 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 448 450 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 451 453 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 550 552 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 661 663 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 752 757 740 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 807 812 795 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 153 159 <span type="species:ncbi:10090">murine</span>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 400 405 <span type="species:ncbi:9606">human</span>
###xml 462 467 <span type="species:ncbi:9606">human</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
Studies of TP73 expression in mature CNS have been limited. In adult mouse brain, TP73 is most highly expressed in the cerebellum [36]. Other studies of murine models have described the crucial role of DeltaNp73 in survival of neurons in the CNS [37,38]. In contrast, TP73 expression and function in normal human brain has not been fully characterized. Others have reported higher TP73 expression in human tumor tissue than in normal brain tissue [39-41]. While human fetal brain reportedly expresses high levels of DeltaNp73 in Cajal-Retzius cells [42], adult cortical and hippocampal neurons apparently express significant levels of both TAp73 and DeltaNp73 [43]. While human cerebellum has not been previously studied, our qRT-RTPCR results confirm TP73 expression in non-neoplastic CNS tissue. Aberrant TP73 expression in the cerebellum may divert developing neurons from normal differentiation, leading to uncontrolled proliferation and medulloblastoma formation.
###end p 91
###begin p 92
###xml 191 196 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 352 357 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 511 513 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 514 516 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 608 612 604 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
We have also confirmed high levels of expression of TAp73 and DeltaNp73 proteins in the same tumors and cell lines. Among different cell types, the apparent discrepancy between expression of TP73 variants at the RNA and protein levels suggests that post-translational modifications also contribute to observed levels. Like other transcription factors, TP73 variants are regulated by a variety of positive and negative networks involving: E2F1, MDM2, Sumo-1, c-Abl, NEDL2, and other DNA damage response factors [21,44]. Such complex regulatory influences probably account for the dynamic expression levels of TP73, as seen with p53.
###end p 92
###begin p 93
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 642 647 642 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
Our analysis of primary medulloblastoma was limited to those specimens with sufficient quantities available as freshly snap frozen tissue suitable for analysis. This fact may represent an unintended selection bias. However, more importantly, none of our findings correlates with histologic subtype or clinical features. Nonetheless, we detected trends toward favorable overall and progression-free survival of patients whose tumors display higher levels of TAp73 RNA, similar to reports in certain adult tumor types [16-19,39]. Future inclusion of additional patients and longer follow-up may increase the strength of the association between TP73 and outcome.
###end p 93
###begin p 94
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 551 553 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 554 556 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 557 559 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 712 721 700 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 738 740 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 883 888 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
TP73 overexpression in medulloblastoma samples compared to normal brain provides potential evidence for p73 isoforms in the growth and treatment response of medulloblastoma. In contrast to normal brain tissue, primary tumor specimens and established medulloblastoma cell lines overexpress both TAp73 and DeltaNp73 proteins, consistent with dysregulation of developmental expression and a possible contribution to their neoplastic phenotype. Functional studies of TAp73 and DeltaNp73 have revealed differential effects in response to genotoxic stress [16,44-46]. TAp73 induces arrest and apoptosis, while in most systems DeltaNp73 counteracts these pathways in response to ionizing radiation and genotoxic agents in vitro [as reviewed in [47]]. In other cell types, DeltaNp73 induces apoptosis instead, underscoring the complexity of p73 isoform function. The frequency and degree of TP73 overexpression in primary medulloblastoma strongly suggests the acquisition of selective advantage(s). Higher relative levels of TAp73 may enhance the apoptotic response of medulloblastoma.
###end p 94
###begin p 95
###xml 168 173 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 353 363 349 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
###xml 569 574 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Since p73 isoforms interact with p53 and can activate common target genes, overexpression of TAp73 and DeltaNp73 may affect medulloblastoma growth via interaction with TP53 and may have functional significance in medulloblastoma. The association between apparent p53 overexpression and clinical outcome in medulloblastoma may not reflect the effects of wild-type p53. Since mutant or dominant negative p53 isoforms are also detected by the nonselective antibodies used, conclusions regarding potential interactions between p53 and p73 cannot be drawn in the absence of TP53 sequencing.
###end p 95
###begin p 96
###xml 504 514 500 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
###xml 628 630 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 631 633 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 804 808 800 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
Etoposide and cisplatin are among the chemotherapeutic drugs important in the treatment of medulloblastoma, and known to activate TAp73. Cisplatin reportedly increases p73 levels by post-translational stabilization, but we detected increased p73 RNA species, most notably the DeltaN'p73 variant, suggesting a component of transcriptional induction. Our results indicate that chemotherapy-induced genotoxic stress induces apoptosis in D283 and Daoy cells. Our results are consistent with studies of other wild-type p53 cell types, including neuroepithelial cells, indicating that VP-16 induces apoptosis in a p53-related manner [48-50]. Furthermore, p53 overexpression alone induces apoptotic cell death, indicating that overexpression of p53 can overcome endogenous negative regulation in D283 cells and TP53-mutation in Daoy cells.
###end p 96
###begin p 97
###xml 193 203 189 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wild-type </italic>
###xml 214 219 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 249 254 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 444 449 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
To address the functional significance of TAp73 and DeltaNp73 overexpression, we transiently transfected medulloblastoma cell lines and examined their survival. Medulloblastoma cell lines with wild-type and mutant TP53 displayed distinct effects of TP73 overexpression. In addition to high levels of basal TAp73 and DeltaNp73 in D283, we found that exogenous TAp73beta and DeltaNp73beta increased apoptosis, especially in response to VP-16. In TP53 mutant Daoy cells, overexpressed TAp73beta and DeltaNp73beta had little effect, even in response to VP-16.
###end p 97
###begin p 98
###xml 646 648 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 649 651 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
In general, overexpression of p53, TAp73beta, and DeltaNp73beta each induced expression of p53/p73 target genes associated with arrest and apoptosis. As expected, knockdown of p53 or TAp73 was associated with reduced expression of these proteins. These results support our TUNEL and flow cytometric data, providing evidence that modulation of p53 and p73 functions can influence chemosensitivity in medulloblastoma. These data suggest that TAp73 regulates apoptosis in medulloblastoma, but is dependent on the p53 status. One possible explanation for this effect is that some forms of mutant p53 can hetero-oligomerize with and inactivate TAp73 [33,51]. Thus, transfected TAp73 may be sequestered in inactive oligomers with mutant p53 preventing activation of p73 pro-apoptotic target genes. In addition to direct interaction with p53, p73 isoforms co-regulate shared downstream transcriptional targets of p53.
###end p 98
###begin p 99
###xml 118 120 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 264 266 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 267 269 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 424 426 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 427 429 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
The initial depiction of DeltaNp73 and TAp73 as either anti- or pro-apoptotic appears oversimplified [as reviewed in [47]]. In fact, various chemotherapeutic agents can induce DeltaNp73 expression in neoplastic cell lines, suggesting a role in apoptotic response [52,53]. Others have noted that constitutive expression of DeltaNp73 isoforms can either resist or increase apoptosis while inducing p53 target gene expression [54,55]. The pro-apoptotic effects of DeltaNp73 have been previously described and may reflect cell type-dependent factors other than specific interactions with p53. These emerging data indicate that the diversity of p73 functions depend upon the cellular context so that the pattern of isoforms expressed may cause pro- or anti-apoptotic effects. These factors add further to the complexity of interpreting the chemosensitizing effects and overabundance of p73 isoforms that we have observed in medulloblastoma. Nonetheless, our results indicate that TAp73 and DeltaNp73 are overexpressed in primary medulloblastoma and demonstrate pro-apoptotic effects similar to those of p53, which may provide mechanisms for modulating tumor cell survival and clinically relevant prognostic information.
###end p 99
###begin title 100
Conclusion
###end title 100
###begin p 101
###xml 202 207 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 269 274 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 587 592 579 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 689 694 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 854 859 846 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 35 42 <span type="species:ncbi:9606">patient</span>
###xml 293 300 <span type="species:ncbi:9606">patient</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 769 776 <span type="species:ncbi:9606">patient</span>
Our analysis of 34 medulloblastoma patient specimens and the medulloblastoma cell lines Daoy and D283 demonstrates significant expression of full-length, TAp73, and amino-terminal-truncated, DeltaNp73, TP73 RNA transcripts and protein. Although the correlation between TP73 RNA expression and patient survival did not achieve statistical significance, there was a trend toward improved overall and progression-free survival in patients whose tumors exhibited high expression of TAp73 RNA. Furthermore, by overexpressing or knocking-down TAp73 or DeltaNp73 expression, we have implicated TP73 isoforms in chemoresponsiveness of medulloblastoma. These results suggest that expression of the TP73 isoform TAp73 in medulloblastomas may be useful as a prognostic marker for patient survival. Our results also suggest that therapeutic strategies that increase TP73 expression may be useful to augment responsiveness of medulloblastomas to chemotherapy.
###end p 101
###begin title 102
List of abbreviations
###end title 102
###begin p 103
qRT-RTPCR, quantitative real-time reverse transcriptase polymerase chain reaction; TUNEL, terminal deoxynucleotidyl transferase-mediated biotinylated-dUTP nick end-labeling; OS, overall survival; PFS, progression-free survival; CDDP, cisplatin; VP-16, etoposide; DOXO, doxorubicin.
###end p 103
###begin title 104
Competing interests
###end title 104
###begin p 105
The author(s) declare that they have no competing interests.
###end p 105
###begin title 106
Authors' contributions
###end title 106
###begin p 107
###xml 186 193 <span type="species:ncbi:9606">patient</span>
RCC, MDB, LLL, JAR, DGS, MSI, and JYHK contributed to expression and functional analyses. RCC, MDB, LP, AMA, MSI, and JYHK analyzed primary tumor pathology, clinical characteristics and patient outcomes. RCC, MDB, and JYHK performed the statistical analyses. AMA, RCC, and JYHK analyzed immunohistochemistry of tumor tissue sections. MSI and JYHK conceived the study, and with RCC and MDB participated in its design, coordination, and manuscript composition. All of the authors made significant contributions to data interpretation, and have read and approved the final manuscript.
###end p 107
###begin title 108
Pre-publication history
###end title 108
###begin p 109
The pre-publication history for this paper can be accessed here:
###end p 109
###begin p 110

###end p 110
###begin title 111
Supplementary Material
###end title 111
###begin title 112
Additional file 1
###end title 112
###begin p 113
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>TP73 </italic>RNA expression in primary medulloblastoma samples</bold>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 392 397 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 467 474 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Columns</italic>
###xml 467 474 447 454 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Columns</italic></bold>
###xml 519 529 499 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 519 529 499 509 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>error bars</italic></bold>
###xml 542 548 520 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y-axis</italic>
###xml 542 548 520 526 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Y-axis</italic></bold>
###xml 613 619 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 577 582 <span type="species:ncbi:9606">human</span>
TP73 RNA expression in primary medulloblastoma samples. Individual primary medulloblastoma samples from patients (n = 34) display overexpression of TAp73 (TA) and 5'-terminal variant RNA species, relative to human fetal brain and normalized to GAPDH expression. By comparison, TP53 RNA is relatively underexpressed. Total DeltaNp73 represents the sum of expression of all 5'-terminal variant TP73 RNA variants (DeltaNp73, DeltaN'p73, DeltaEx2p73, and DeltaEx2/3p73). Columns, mean expression of at least 2 experiments; error bars, +/- S.E.M. Y-axis, RNA expression relative to human fetal brain and normalized to GAPDH expression (N.B. log-scale).
###end p 113
###begin p 114
Click here for file
###end p 114
###begin title 115
Additional file 2
###end title 115
###begin p 116
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Primary medulloblastoma samples express p53 protein</bold>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
Primary medulloblastoma samples express p53 protein. Western blot analysis reveals that individual primary medulloblastoma samples from patients express p53 (internally normalized to beta-actin expression and relative to D283 cells).
###end p 116
###begin p 117
Click here for file
###end p 117
###begin title 118
Additional file 3
###end title 118
###begin p 119
###xml 0 73 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAp73 and &#916;Np73 protein expression in primary medulloblastoma samples</bold>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
TAp73 and DeltaNp73 protein expression in primary medulloblastoma samples. Western blot analysis reveals that individual primary medulloblastoma samples from patients display overexpression of full-length TAp73 and amino-terminal truncated DeltaNp73 (internally normalized to beta-actin expression and relative to D283 cells).
###end p 119
###begin p 120
Click here for file
###end p 120
###begin title 121
Additional file 4
###end title 121
###begin p 122
###xml 0 18 0 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Apoptosis analysis</bold>
###xml 120 121 120 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 123 125 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 247 253 247 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X-axis</italic>
###xml 247 253 247 253 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>X-axis</italic></bold>
###xml 355 361 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y-axis</italic>
###xml 355 361 354 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Y-axis</italic></bold>
Apoptosis analysis. TUNEL assay of D283 cell line confirms apoptotic changes in PI-stained cell populations in the sub-G0/G1 peak (i.e. hypodiploid (less than 2n) DNA content, representing apoptotic nuclei) detected using flow cytometric methods. X-axis, transfected plasmids (described in text) and post-transfection culture conditions (VP-16, 1.5 muM); Y-axis, % of cells with apoptotic features by flow cytometry or TUNEL assay.
###end p 122
###begin p 123
Click here for file
###end p 123
###begin title 124
Acknowledgements
###end title 124
###begin p 125
###xml 60 68 <span type="species:ncbi:9606">Children</span>
We thank Diana Joo Youn Hwang, Sowmya Paturi, and the Texas Children's Cancer Center Flow Cytometry Core Laboratory for technical assistance; Carolyn Pena for administrative support; Ching Lau for assistance with tissue procurement; Donald L. Durden and Rita Nahta for helpful discussions. This work was supported by funding from: Associazione Italiana contro le Leucemie (MDB); John S. Dunn Research Foundation; NIH grants HD042977 (RCC) and NS043517 (JYHK); The Terry Fox Foundation of the National Cancer Institute of Canada, the James Birrell Neuroblastoma Research Fund (MSI); The American Cancer Society, The Baylor College of Medicine Cancer Center, The Brain Tumor Society, The Childhood Brain Tumor Foundation, the Gillson Longenbaugh Foundation, and John and Carroll Goodman (JYHK).
###end p 125
###begin article-title 126
Medulloblastoma
###end article-title 126
###begin article-title 127
Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results
###end article-title 127
###begin article-title 128
Current treatment of medulloblastoma: recent advances and future challenges
###end article-title 128
###begin article-title 129
###xml 24 29 <span type="species:ncbi:9606">human</span>
TP53 family members and human cancers
###end article-title 129
###begin article-title 130
###xml 31 36 <span type="species:ncbi:9606">human</span>
p53 mutations in nonastrocytic human brain tumors
###end article-title 130
###begin article-title 131
Decision making by p53: life, death and cancer
###end article-title 131
###begin article-title 132
Infrequent p53 gene mutations in medulloblastomas
###end article-title 132
###begin article-title 133
The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma
###end article-title 133
###begin article-title 134
###xml 102 110 <span type="species:ncbi:10632">JC virus</span>
Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus
###end article-title 134
###begin article-title 135
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched
###end article-title 135
###begin article-title 136
Cytogenetics and molecular genetics of childhood brain tumors
###end article-title 136
###begin article-title 137
Classifying the medulloblastoma: insights from morphology and molecular genetics
###end article-title 137
###begin article-title 138
###xml 110 115 <span type="species:ncbi:9606">human</span>
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
###end article-title 138
###begin article-title 139
An anti-apoptotic role for the p53 family member, p73, during developmental neuron death
###end article-title 139
###begin article-title 140
Neuronal survival and p73/p63/p53: a family affair
###end article-title 140
###begin article-title 141
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo
###end article-title 141
###begin article-title 142
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo
###end article-title 142
###begin article-title 143
###xml 58 63 <span type="species:ncbi:9606">human</span>
DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1
###end article-title 143
###begin article-title 144
Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score
###end article-title 144
###begin article-title 145
###xml 73 78 <span type="species:ncbi:9606">human</span>
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73
###end article-title 145
###begin article-title 146
Transactivation-deficient DeltaTA-p73 acts as an oncogene
###end article-title 146
###begin article-title 147
###xml 88 93 <span type="species:ncbi:9606">human</span>
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors
###end article-title 147
###begin article-title 148
Mutation analysis of the p73 gene in nonastrocytic brain tumours
###end article-title 148
###begin article-title 149
###xml 41 48 <span type="species:ncbi:9606">infants</span>
###xml 53 61 <span type="species:ncbi:9606">children</span>
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001)
###end article-title 149
###begin article-title 150
###xml 43 50 <span type="species:ncbi:9606">infants</span>
###xml 66 74 <span type="species:ncbi:9606">children</span>
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience
###end article-title 150
###begin article-title 151
###xml 13 21 <span type="species:ncbi:9606">children</span>
###xml 122 130 <span type="species:ncbi:9606">Children</span>
Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study
###end article-title 151
###begin article-title 152
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study
###end article-title 152
###begin article-title 153
IARC TP53 Mutation Database
###end article-title 153
###begin article-title 154
Sanger Center Cancer Cell Line Project
###end article-title 154
###begin article-title 155
A new mathematical model for relative quantification in real-time RT-PCR
###end article-title 155
###begin article-title 156
Two new p73 splice variants, gamma and delta, with different transcriptional activity
###end article-title 156
###begin article-title 157
Chemosensitivity linked to p73 function
###end article-title 157
###begin article-title 158
Viral oncoproteins discriminate between p53 and the p53 homolog p73
###end article-title 158
###begin article-title 159
Multiple stress signals induce p73beta accumulation
###end article-title 159
###begin article-title 160
New antibodies recognizing p73: comparison with commercial antibodies
###end article-title 160
###begin article-title 161
Brain Gene Expression Map
###end article-title 161
###begin article-title 162
Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms
###end article-title 162
###begin article-title 163
p73 is required for survival and maintenance of CNS neurons
###end article-title 163
###begin article-title 164
###xml 24 29 <span type="species:ncbi:9606">human</span>
p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas
###end article-title 164
###begin article-title 165
Overexpression of the wild type p73 gene in breast cancer tissues and cell lines
###end article-title 165
###begin article-title 166
Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis
###end article-title 166
###begin article-title 167
###xml 47 52 <span type="species:ncbi:9606">human</span>
Expression of p73 and Reelin in the developing human cortex
###end article-title 167
###begin article-title 168
###xml 70 75 <span type="species:ncbi:9606">human</span>
Multiple isoforms of the tumor protein p73 are expressed in the adult human telencephalon and choroid plexus and present in the cerebrospinal fluid
###end article-title 168
###begin article-title 169
Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo
###end article-title 169
###begin article-title 170
Chemosensitivity linked to p73 function
###end article-title 170
###begin article-title 171
DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest
###end article-title 171
###begin article-title 172
DeltaNp73: misunderstood protein?
###end article-title 172
###begin article-title 173
Etoposide induces apoptosis and cell cycle arrest of neuroepithelial cells in a p53-related manner
###end article-title 173
###begin article-title 174
G2 arrest in response to topoisomerase II inhibitors: the role of p53
###end article-title 174
###begin article-title 175
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer
###end article-title 175
###begin article-title 176
p73 function is inhibited by tumor-derived p53 mutants in mammalian cells
###end article-title 176
###begin article-title 177
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
###end article-title 177
###begin article-title 178
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis
###end article-title 178
###begin article-title 179
DeltaNp73beta is active in transactivation and growth suppression
###end article-title 179
###begin article-title 180
Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or not
###end article-title 180

